Friday, January 6, 2012

Jazz closes up more than 9% on brighter profit outlook

Jazz Pharmaceuticals Inc.'s stock closed Friday at $45.39 per share, up 9.49 percent.
The jump comes following the Palo Alto-based specialty pharmaceutical company (NASDAQ:JAZZ) saying Thursday it is expecting a larger profit in 2012, following its purchase of Azur Pharma Ltd. The deal witth Azur is expected to close the week of Jan. 16.
It also said sales of its narcolepsy drug, Xyrem, have done well.

No comments:

Post a Comment